{
    "clinical_study": {
        "@rank": "23536", 
        "arm_group": [
            {
                "arm_group_label": "No Family History of Psychosis (FHN)", 
                "arm_group_type": "Other", 
                "description": "Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions."
            }, 
            {
                "arm_group_label": "Family History of Psychosis (FHP)", 
                "arm_group_type": "Experimental", 
                "description": "Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions."
            }
        ], 
        "brief_summary": {
            "textblock": "The overall purpose of this study is to determine whether a family history of psychosis is\n      associated with an altered cannabinoid system. This will be tested by studying individuals\n      with and without a family history of psychosis and comparing their responses to delta\n      9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that\n      compared to controls with no family history of psychoses, individuals with a family history\n      of psychoses will have an altered response to THC."
        }, 
        "brief_title": "Probing the Cannabinoid System in Individuals With a Family History of Psychosis", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Psychosis", 
            "Schizotypy", 
            "Cannabis Use"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria FHP:\n\n          -  Exposure to cannabis at least once in their lifetime\n\n          -  Medically and psychiatrically healthy based on screening\n\n          -  Having one relative with a confirmed psychotic disorder\n\n        Exclusion Criteria FHP:\n\n          -  Current or lifetime major DSM-IV Axis I disorder\n\n          -  Current or lifetime treatment (at least 6 months) with psychotropic medications for\n             major psychiatric or neurological illness\n\n          -  Major or unstable medical illness that might impact safety of the subject in the\n             study\n\n          -  Cannabis naive\n\n          -  IQ less than 85\n\n          -  Less than a high school diploma or its educational equivalent\n\n          -  Pregnancy or lactation\n\n          -  Major current or recent (<6 weeks) psychosocial stressors.\n\n        Inclusion Criteria FHN :\n\n          -  Exposure to cannabis at least once in their lifetime\n\n          -  Medically and psychiatrically healthy based on screening\n\n        Exclusion Criteria FHN:\n\n          -  Having a family member with psychosis\n\n          -  Current or lifetime major DSM-IV Axis I disorder\n\n          -  Current or lifetime treatment (at least 6 months) with psychotropic medications for\n             major psychiatric or neurological illness\n\n          -  Major or unstable medical illness that might impact safety of the subject in the\n             study\n\n          -  Cannabis naive\n\n          -  IQ less than 85\n\n          -  Less than a high school diploma or its educational equivalent\n\n          -  Pregnancy or lactation\n\n          -  Major current or recent (<6 weeks) psychosocial stressors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102113", 
            "org_study_id": "HIC1310012948"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "No Family History of Psychosis (FHN)", 
                    "Family History of Psychosis (FHP)"
                ], 
                "description": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "No Family History of Psychosis (FHN)", 
                    "Family History of Psychosis (FHP)"
                ], 
                "description": "Subjects will receive 0.010mg/kg.", 
                "intervention_name": "Very Low Dose THC", 
                "intervention_type": "Drug", 
                "other_name": "delta 9-tetrahydrocannabinol"
            }, 
            {
                "arm_group_label": [
                    "No Family History of Psychosis (FHN)", 
                    "Family History of Psychosis (FHP)"
                ], 
                "description": "Subjects will receive 0.018 mg/kg over 20 minutes.", 
                "intervention_name": "Low Dose THC", 
                "intervention_type": "Drug", 
                "other_name": "delta 9-tetrahydrocannabinol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrocannabinol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "contact": {
                "email": "prerana.purohit@yale.edu", 
                "last_name": "Prerana Purihot", 
                "phone": "203-932-5711", 
                "phone_ext": "4495"
            }, 
            "facility": {
                "address": {
                    "city": "West Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06516"
                }, 
                "name": "VA Connecticut Healthcare System"
            }, 
            "investigator": {
                "last_name": "Mohini Ranganathan", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Probing the Cannabinoid System in Individuals With a Family History of Psychosis", 
        "overall_contact": {
            "email": "prerana.purohit@yale.edu", 
            "last_name": "Prerana Purohit", 
            "phone": "203-932-5711", 
            "phone_ext": "4495"
        }, 
        "overall_official": {
            "affiliation": "MYSM School Of Medicine", 
            "last_name": "Mohini Ranganathan", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.", 
                "measure": "Positive and Negative Symptom Scale for Schizophrenia (PANSS)", 
                "safety_issue": "No", 
                "time_frame": "-30 min from administration of THC"
            }, 
            {
                "description": "Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.", 
                "measure": "Positive and Negative Symptom Scale for Schizophrenia (PANSS)", 
                "safety_issue": "No", 
                "time_frame": "+80 min from administration of THC"
            }, 
            {
                "description": "Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.", 
                "measure": "Positive and Negative Symptom Scale for Schizophrenia (PANSS)", 
                "safety_issue": "No", 
                "time_frame": "+150 min of administration of THC"
            }, 
            {
                "description": "Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.", 
                "measure": "Positive and Negative Symptom Scale for Schizophrenia (PANSS)", 
                "safety_issue": "No", 
                "time_frame": "+240 min of administration of THC"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102113"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.", 
                "measure": "Clinician Administered Dissociative Symptoms Scale (CADSS)", 
                "safety_issue": "No", 
                "time_frame": "-30 min, +15 min, +80 min, +150 min, +240 min"
            }, 
            {
                "description": "Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states (\"high\", \"anxious\", \"calm and relaxed\", and \"tired\") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects.", 
                "measure": "Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "-30 min, +15 min, +80 min, +150 min, +240 min"
            }, 
            {
                "description": "The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects.", 
                "measure": "Hopkins Verbal Learning Test (HVLT)", 
                "safety_issue": "No", 
                "time_frame": "+50 min"
            }, 
            {
                "description": "The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC.", 
                "measure": "Psychotomimetic States Inventory (PSI)", 
                "safety_issue": "No", 
                "time_frame": "-30 min, +240 min"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}